NEW YORK, Oct. 4, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) (“NeoStem” or the “Company”), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company and its wholly-owned subsidiary, Progenitor Cell Therapy (“PCT”), will be presenting at three upcoming October conferences: the 2011 World Stem Cell Summit, the AABB Annual Meeting & CTTXPO, and Cell Therapy Bioprocessing.
2011 World Stem Cell Summit October 3-5, 2011, Pasadena, California Convention Center
3:45 PM on Tuesday, October 4 - Jason Kolbert, NeoStem’s VP of Strategic Business Development, will moderate an industry session entitled “The Paradigm Shift to Cell Based Medicine: How Investors Can Discern True Value.”
12 PM on Wednesday, October 5 - Dr. Robin L. Smith, Chairman and CEO of NeoStem, Inc. will also speak at the World Stem Cell Summit in an industry session entitled “Financing Pathways for Stem Companies and Novel Funding Options.”
AABB Annual Meeting & CTTXPO October 22-25, 2011, San Diego, California San Diego Convention Center
10:30 AM on Saturday, October 22 - Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, will speak on a panel entitled “Cellular Therapy Product Development Using Project Management Techniques.”
Cell Therapy Bioprocessing October 17-18, 2011, Reston, Virginia Hyatt Regency Reston
11:15 AM on Monday, October 17 - Karen Trujillo, BSc, Director of the Mountain View Facility for PCT, will give a presentation on the “Development of Lot Release Assays During Product Development.”
Dr. Robin L. Smith said, “We are delighted to participate in this significant conference. In addition to sharing our knowledge of the industry, we consider this event an excellent platform to speak about our business lines. NeoStem endeavors to be an integrative force in the cell therapy industry. By vertically integrating the collection, storage and processing of cell units and the development, manufacturing, distribution, and delivery of cell therapy products, we are positioned to take advantage of growth in the cell therapy industry as a whole.”
Jason Kolbert said, “As co-chair of a dynamic panel at the World Stem Cell Summit, I look forward to raising investors’ awareness of the opportunities for cell therapy companies to continue to develop and create value in the healthcare system by bringing new cost-effective therapies that can address unmet medical needs to the marketplace. We have seen many paradigm shifts in the biotechnology industry from monoclonal antibodies to viral disease. We foresee cell therapy as among the next great opportunities in the biotechnology space and are thrilled to be adding to our clinical assets, through our Amorcyte, Inc. merger, AMR-001 for the preservation of heart function post heart attack as we believe this will be an important asset that will help drive this paradigm shift.”
Robert A. Preti, PhD, said, “PCT is excited to have these venues in the coming month to demonstrate our leadership in cell therapy development, manufacturing, quality assurance, regulatory consulting, and more. At PCT we embrace the need for regulation of cell therapies, and work constructively with the both the public and private sector where appropriate. With the development of NeoStem’s cell therapeutics, we are taking the approach of developing therapies along the lines of more traditional drugs, so that the issues of potency, purity, identity, and stability - all of those components that pharmaceutical and biologics companies think about - are considered. It is in this regard that we value our relationships with professional associations such as AABB, whose membership is involved in the manufacture and distribution of living, licensed products for the healthcare community.”
About NeoStem, Inc.
NeoStem is a leader in the development and manufacturing of cell therapies. The Company’s strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC and global reach has positioned the company for breakthroughs in the cell therapy industry. The acquisition of Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) will position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. NeoStem is also pursuing a T-cell therapeutic with potential in a range of auto-immune conditions and development of its VSEL Technology platform. For more information on NeoStem, please visit www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s prospectus supplement filed with the Securities and Exchange Commission on September 30, 2011. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact:
NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: rsmith@neostem.com
Web: http://www.neostem.com
SOURCE NeoStem, Inc.
